DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2245517/wall-street-analysts-see-a-71-71-upside-in-phunware-phun-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2245517 Mar 25, 2024 - The mean of analysts' price targets for Phunware (PHUN) points to a 71.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. 0

https://www.zacks.com/stock/news/2246359/plains-all-american-pipeline-paa-sees-a-more-significant-dip-than-broader-market-some-facts-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2246359 Mar 26, 2024 - In the latest trading session, Plains All American Pipeline (PAA) closed at $17.07, marking a -0.52% move from the previous day. 0

https://www.zacks.com/stock/news/2245941/wall-street-analysts-see-qualcomm-qcom-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2245941 Mar 26, 2024 - The average brokerage recommendation (ABR) for Qualcomm (QCOM) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock? 0

https://www.zacks.com/stock/news/2247409/wall-street-analysts-see-a-25-67-upside-in-burford-capital-bur-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2247409 Mar 28, 2024 - The consensus price target hints at a 25.7% upside potential for Burford Capital (BUR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. 0

https://www.zacks.com/stock/news/2247411/wall-street-analysts-see-an-82-29-upside-in-xperi-xper-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2247411 Mar 28, 2024 - The average of price targets set by Wall Street analysts indicates a potential upside of 82.3% in Xperi (XPER). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. 0

https://www.zacks.com/commentary/2247686/can-we-see-more-upside-with-this-stock-market-rally?cid=CS-ZC-FT-spoken_word-2247686 Mar 28, 2024 - Oftentimes, strong momentum trading leads to more momentum. 0

https://www.zacks.com/stock/news/2248304/wall-street-analysts-see-nvidia-nvda-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2248304 Apr 01, 2024 - According to the average brokerage recommendation (ABR), one should invest in Nvidia (NVDA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock? 0

https://www.zacks.com/stock/news/2249701/wall-street-analysts-see-avidxchange-avdx-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2249701 Apr 03, 2024 - Based on the average brokerage recommendation (ABR), AvidXchange (AVDX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying? 0

https://www.zacks.com/stock/news/2250422/wall-street-analysts-see-ge-healthcare-gehc-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2250422 Apr 04, 2024 - Based on the average brokerage recommendation (ABR), GE HealthCare (GEHC) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying? 0

https://www.zacks.com/stock/news/2251973/wall-street-analysts-see-a-218-92-upside-in-annovis-bio-anvs-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2251973 Apr 08, 2024 - The average of price targets set by Wall Street analysts indicates a potential upside of 218.9% in Annovis Bio (ANVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. 0